Table 4B.
Influence of dosage, timing and injection times of omalizumab.
| tIgE(KU/L) | CSMS without omalizumab | CSMS with omalizumab | CSMS improvement | Recovery rate1 | |
|---|---|---|---|---|---|
| Date of first injection | |||||
| 2 weeks in advance (n=24) | 129.0[74.9,216.0] | 3.67[2.67,4.79] | 0.50[0.00,1.67] | 2.69 ± 0.25 | 7(29.2%) |
| 2-4 weeks in advance (n=20) | 234.5[70.3,643.5] | 4.50[3.04,5.00] | 0.83[0.00,2.34] | 2.78 ± 0.36 | 6(30.0%) |
| 4-10 weeks in advance (n=20) | 160.0[114.0,513.8] | 4.33[2.83,5.00] | 1.00[0.09,1.92] | 2.79 ± 0.33 | 6(30.0%) |
| P-value | 0.468 | 0.235 | 0.729 | 0.923 | 0.998 |
| Injection times | |||||
| Single time (n=18) | 205.0[108.9,337.5] | 4.00[2.96,4.54] | 0.75[0.00,2.00] | 2.42 ± 1.18 | 5(27.8%) |
| Multiple times (n=46) | 129.0[74.9,417.0] | 4.42[2.79,5.00] | 0.59[0.00,1.67] | 2.88 ± 1.49 | 14(30.4%) |
| P-value | 0.585 | 0.513 | 0.458 | 0.243 | 0.834 |
| Dosage3 | |||||
| 150mg(n-14) | 63.0[40.3,100.0] | 4.83[2.83,5.00] | 1.00[0.33,2.00] | 2.57 ± 0.50 | 2(14.3%) |
| 300mg(n=39) | 153.0[114.5,484.5] | 3.17[2.42,4.25] | 0.67[0.00,1.67] | 2.49 ± 0.25 | 13(33.3%) |
| 450-600mg(n=11) | 389.5[239.3,1372.0] | 3.84[3.50,4.63] | 0.34[0.00,0.96] | 3.44 ± 0.47 | 4(36.4%) |
| P-value | 0.000 | 0.253 | 0.442 | 0.634 | 0.354 |